Clearmind Medicine Appoints Mary-Elizabeth Gifford as Chief of Global Impact to Advance US Partnerships and Governmental Engagement

Core Insights - Clearmind Medicine Inc. has appointed Mary-Elizabeth Gifford as Chief of Global Impact to enhance US partnerships and regulatory advocacy in the psychedelic medicine sector [1][3] Company Overview - Clearmind is a clinical-stage biotech company focused on developing novel neuroplastogens-derived therapeutics to address under-treated health issues, including alcohol use disorder [4] - The company holds an intellectual property portfolio consisting of 19 patent families with 31 granted patents and aims to expand this portfolio opportunistically [5] Leadership and Expertise - Mary-Elizabeth Gifford previously served as Chief of Global Impact at Psyence BioMed and has extensive experience in psychedelic policies and regulatory landscapes [2][3] - Gifford has been recognized as a significant figure in the psychedelic industry, being named a "Psychedelic Titan" and described as "the most quietly influential woman working in psychedelics today" [3] Strategic Initiatives - Gifford's role will focus on bridging research, regulation, and patient care to accelerate the advancement of innovative psychedelic medicines [1][3] - Clearmind is conducting clinical trials at prestigious institutions such as Yale School of Medicine and Johns Hopkins University, aiming to set industry standards for scientific rigor [3]